Cite
HARVARD Citation
Aboud, M. et al. (2019). Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared with lopinavir/ritonavir (LPV/r) Plus 2 NRTIs in Second-Line Treatment — 48-week Data from the DAWNING Study. Journal of infection and public health. 12 (1), pp. 107-. [Online].